Harbour BioMed Reports Phase I Success for HBM9378 Antibody
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
biologics
Advertisement
Voro Therapeutics Partners with Daiichi Sankyo on ADCs
SAN DIEGO, CA, March 17, 2026 Voro Therapeutics has announced a research collaboration with Daiichi Sankyo to advance its...
Manifold Bio Demonstrates AI Protein Design Breakthrough
Boston, Massachusetts, March 16, 2026 Manifold Bio, a platform therapeutics company focused on AI-driven drug discovery, announced breakthrough results...
TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Gazyva Phase III Success in Autoimmune Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2026 — Genentech announced positive Phase III clinical trial results showing that Gazyva®...
Advertisements
KSI-101 Phase 1b Data Advance Inflammatory Macular Therapy
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
FDA Expands Regulatory Flexibility for Cell and Gene Therapies
White Oak, Maryland – January 2026 — The U.S. Food and Drug Administration has announced a more flexible regulatory...
Apogee Shows Durable Phase 1b Asthma Data for IL-13 Biologic
SAN FRANCISCO & BOSTON | January 6, 2026 — Apogee Therapeutics has reported positive interim results from a Phase...
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
Innovent’s PECONDLE Gains NMPA Approval as China’s First IL-23p19 Antibody
SAN FRANCISCO & SUZHOU, China — November 28, 2025. Innovent Biologics has announced that PECONDLE® (picankibart injection), a recombinant...
Advertisement
